MedTrace Logo

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

NCT00222235 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2019-08-20

No results posted yet for this study

Summary

This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia.

Conditions

Interventions

DRUG

d-cycloserine

DRUG

glycine

DRUG

placebo

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • The Zucker Hillside Hospital

    collaborator OTHER

  • Nathan Kline Institute for Psychiatric Research

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • Sarah Herzog Hospital

    collaborator UNKNOWN

  • University of Maryland, College Park

    collaborator OTHER

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • William T Carpenter, MD · Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicien

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
54 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2004-06-30
Completion
2004-06-30

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222235 on ClinicalTrials.gov